title: Demonstration in vivo of reduced serotonin responsivity in the brain of untreated depressed patients.
abstract: OBJECTIVE
  For over 25 years, it has been hypothesized that major depression is due to a deficiency of available serotonin or subsensitivity of key serotonin receptors in relevant brain regions. Direct evidence supporting this hypothesis has been lacking because of the difficulty in studying regional brain serotonergic function. The authors have developed a method for visualizing in vivo regional brain responses to serotonin release by comparing regional brain glucose metabolism after administration of the serotonin-releasing drug dl-fenfluramine, relative to placebo.
  
  
  METHODS
  Results with healthy subjects (N = 6) were compared to those obtained with drug-free inpatients with moderately severe major depression (N = 6).
  
  
  RESULTS
  Healthy subjects had several areas of statistically significant increases in metabolism, mostly in the left prefrontal and temporoparietal cortex, and areas of decreased metabolism, such as in the right prefrontal cortex. In contrast, the depressed patients had no areas of increase or decrease in metabolism, differing significantly from healthy subjects. Results with patients resembled those with healthy subjects (N = 10) who were scanned twice without active drug on either occasion.
  
  
  CONCLUSIONS
  This study provides the first direct visualization of blunted regional brain responses to serotonin release in the brain of patients with major depression, a finding that supports the hypothesis of impaired serotonergic transmission in depression.
authors.affiliation: Department of Neuroscience, New York State Psychiatric Institute, NY 10032, USA.
authors.forename: J J
authors.initials: JJ
authors.lastname: Mann
authors.forename: K M
authors.initials: KM
authors.lastname: Malone
authors.forename: D J
authors.initials: DJ
authors.lastname: Diehl
authors.forename: J
authors.initials: J
authors.lastname: Perel
authors.forename: T B
authors.initials: TB
authors.lastname: Cooper
authors.forename: M A
authors.initials: MA
authors.lastname: Mintun
mesh_terms: D000328:Adult; D001921:Brain / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000378:metabolism; D003847:Deoxyglucose / Q000031:analogs & derivatives; D003866:Depressive Disorder / Q000000981:diagnostic imaging / Q000378:metabolism* / Q000503:physiopathology; D005260:Female; D005277:Fenfluramine / Q000097:blood / Q000494:pharmacology*; D019788:Fluorodeoxyglucose F18; D005947:Glucose / Q000378:metabolism; D006760:Hospitalization; D006801:Humans; D008297:Male; D009642:Norfenfluramine / Q000097:blood; D010296:Parietal Lobe / Q000378:metabolism; D017397:Prefrontal Cortex / Q000378:metabolism; D011388:Prolactin / Q000097:blood; D011985:Receptors, Serotonin / Q000187:drug effects / Q000378:metabolism / Q000502:physiology; D012701:Serotonin / Q000378:metabolism / Q000502:physiology; D018490:Serotonin Agents / Q000494:pharmacology*; D013702:Temporal Lobe / Q000378:metabolism; D014055:Tomography, Emission-Computed
chemical_list: D011985:Receptors, Serotonin; D018490:Serotonin Agents; D019788:Fluorodeoxyglucose F18; D009642:Norfenfluramine; D005277:Fenfluramine; D012701:Serotonin; D011388:Prolactin; D003847:Deoxyglucose; D005947:Glucose